Why I think it might finally be time to buy FTSE 100 dividend stock GlaxoSmithKline

Shares in drugmaker GlaxoSmithKline plc (LON:GSK) responded well to an update on trading. Paul Summers likes the stock a lot more than he used to.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

In keeping with its tradition of releasing results in time to catch US markets opening, pharmaceuticals giant GlaxoSmithKline (LSE: GSK) revealed its latest trading update at noon today.

Given the (initial) increase in the share price this afternoon, it seems many UK investors are more than satisfied with what the Brentford-based business had to say.

Sales up

Group sales over the third quarter of its financial year hit £8.1bn — a rise of 6% at constant exchange rates (CER).  This brings the drugmaker’s total turnover for the first nine months to £22.6bn — 4% higher once currency fluctuations are taken into account. At £4.2bn, the majority of this came from its Pharmaceuticals business. Sales at Consumer Healthcare and Vaccines — Glaxo’s two other businesses — both rose to £1.9bn with the latter registering growth of 17%. 

Total New Respiratory product sales soared 40% to £645m over the reporting period with the company’s Relvar Ellipta inhalers and add-on treatment Nucala bringing in £500m and £145m respectively. Elsewhere, sales of HIV drugs Tivicay and Triumeq climbed 13% to £1.1bn. 

Taking all this into account, adjusted operating profit grew 6% over the period to £2.52bn and 7% over the first nine months to £6.55bn. Adjusted earnings per share came in at a better-than-expected 35.5p (+14% CER)

Positively for those already holding its stock, Glaxo announced today that it would be revising its guidance for the full year “towards the upper end of previous expectations“. Thanks to bumper sales of Shingrix (likely to be £700m-£750m in the current financial year after bringing in £286m over Q3) and improved cost control, adjusted earnings per share growth of between 8%-10% at constant exchange rates is now predicted.  Interestingly, this is regardless of whether a generic competitor to its blockbuster Advair — used to prevent asthma attacks by relaxing muscles in the airways — is introduced in the US. 

A screaming buy?

GlaxoSmithKline’s stock was trading a little under 14 times earnings before trading commenced this morning. Compared to other companies in its industry, that’s pretty cheap. It’s certainly better valued than FTSE 100 peer Astrazeneca, which requires investors to fork out 22 times earnings to acquire its stock at the current time, although the latter does arguably have better growth prospects going forward.

The real draw for many investors, however, remains Glaxo’s bumper yield. As expected, the company revealed a 19p per share dividend for the quarter. A total payout of 80p for the financial year was also reiterated — something that hasn’t changed since 2014.

Based on its today’s share price, that leaves Glaxo yielding 5.2%. While I don’t expect significant hikes going forward, the extent to which these cash returns are likely to be covered by profits is beginning to look far healthier. I fully confess to being sceptical over the company’s ability to avoid taking a knife to its dividend over the last couple of years but, at £2.38bn, the 42% improvement in free cash flow over the year to date makes Glaxo’s income credentials a lot stronger. 

It might not be a screaming buy, but today’s numbers have led me to revise my view on the company. At a time when many investors are clamouring for security as a response to ongoing trade tensions between the US and China, to interest rate rises and our forthcoming EU departure, I think purchasing slices of non-cyclical, globally diversified businesses like Glaxo could be a sound move. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Paul Summers has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »

Investing Articles

Are HSBC shares a FTSE bargain? Here’s what the charts say!

There are plenty of dirt-cheap FTSE 100 banking stocks for investors to choose from today. Our writer Royston Wild believes…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Just released: Share Advisor’s latest ‘Hold’ recommendation [PREMIUM PICKS]

In our Share Advisor newsletter service, we provide buy, sell, and hold guidance for our universe of recommendations.

Read more »

Investing Articles

Investing £5 a day could help me build a second income of £329 a month!

This Fool explains how £5 a day, or one less takeaway coffee, could help her build a monthly second income…

Read more »